KalVista Pharmaceuticals, Inc.
KALV
$27.00
$0.010.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 07/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 54.69% | 88.93% | -- | -48.59% | -16.10% |
| Total Depreciation and Amortization | 41.43% | 156.11% | -- | 12.50% | 14.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 393.14% | 123.04% | -- | 334.86% | -79.49% |
| Change in Net Operating Assets | -396.74% | -332.00% | -- | -103.42% | -91.51% |
| Cash from Operations | 69.61% | 113.93% | -- | -35.51% | -214.91% |
| Capital Expenditure | 57.99% | -2,806.25% | -- | -1,280.95% | -1,820.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.26% | 3.78% | -- | -42.04% | 97.28% |
| Cash from Investing | 75.77% | -4.26% | -- | -42.79% | 97.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -34.10% | -- | -- | -57.03% | -97.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -88.19% | -- | -- | -- |
| Cash from Financing | -34.10% | -47.57% | -- | 673.67% | -98.52% |
| Foreign Exchange rate Adjustments | -175.13% | -443.51% | -- | 2,227.35% | 3,127.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 66.74% | -32.34% | -- | -12,486.44% | -636.15% |